Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

GN. Hortobagyi, SM. Stemmer, HA. Burris, YS. Yap, GS. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, KL. Blackwell, EP. Winer, W. Janni, S. Verma, P. Conte, CL. Arteaga, DA. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliegy, C. Germa, J....

. 2018 ; 29 (7) : 1541-1547. [pub] 20180701

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045470

Background: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here, we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. Patients and methods: A total of 668 postmenopausal women with HR+, HER2- recurrent/metastatic breast cancer were randomized (1 : 1; stratified by presence/absence of liver and/or lung metastases) to ribociclib (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole. The primary end point was locally assessed PFS. The key secondary end point was overall survival (OS). Other secondary end points included overall response rate (ORR) and safety. Biomarker analysis was an exploratory end point. Results: At the time of the second interim analysis, the median duration of follow-up was 26.4 months. Median PFS was 25.3 months [95% confidence interval (CI) 23.0-30.3] for ribociclib plus letrozole and 16.0 months (95% CI 13.4-18.2) for placebo plus letrozole (hazard ratio 0.568; 95% CI 0.457-0.704; log-rank P = 9.63 × 10-8). Ribociclib treatment benefit was maintained irrespective of PIK3CA or TP53 mutation status, total Rb, Ki67, or p16 protein expression, and CDKN2A, CCND1, or ESR1 mRNA levels. Ribociclib benefit was more pronounced in patients with wild-type versus altered receptor tyrosine kinase genes. OS data remain immature, with 116 deaths observed; 50 in the ribociclib arm and 66 in the placebo arm (hazard ratio 0.746; 95% CI 0.517-1.078). The ORR was 42.5% versus 28.7% for all patients treated with ribociclib plus letrozole versus placebo plus letrozole, respectively, and 54.5% versus 38.8%, respectively, for patients with measurable disease. Safety results, after a further 11.1 months of follow-up, were comparable with those reported at the first analysis, with no new or unexpected toxicities observed, and no evidence of cumulative toxicity. Conclusions: The improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole are maintained with longer follow-up, relative to letrozole monotherapy. Clinical trials number: NCT01958021.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045470
003      
CZ-PrNML
005      
20200113082244.0
007      
ta
008      
200109s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdy155 $2 doi
035    __
$a (PubMed)29718092
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hortobagyi, G N $u Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
245    10
$a Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer / $c GN. Hortobagyi, SM. Stemmer, HA. Burris, YS. Yap, GS. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, KL. Blackwell, EP. Winer, W. Janni, S. Verma, P. Conte, CL. Arteaga, DA. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliegy, C. Germa, J. O'Shaughnessy,
520    9_
$a Background: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here, we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. Patients and methods: A total of 668 postmenopausal women with HR+, HER2- recurrent/metastatic breast cancer were randomized (1 : 1; stratified by presence/absence of liver and/or lung metastases) to ribociclib (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole. The primary end point was locally assessed PFS. The key secondary end point was overall survival (OS). Other secondary end points included overall response rate (ORR) and safety. Biomarker analysis was an exploratory end point. Results: At the time of the second interim analysis, the median duration of follow-up was 26.4 months. Median PFS was 25.3 months [95% confidence interval (CI) 23.0-30.3] for ribociclib plus letrozole and 16.0 months (95% CI 13.4-18.2) for placebo plus letrozole (hazard ratio 0.568; 95% CI 0.457-0.704; log-rank P = 9.63 × 10-8). Ribociclib treatment benefit was maintained irrespective of PIK3CA or TP53 mutation status, total Rb, Ki67, or p16 protein expression, and CDKN2A, CCND1, or ESR1 mRNA levels. Ribociclib benefit was more pronounced in patients with wild-type versus altered receptor tyrosine kinase genes. OS data remain immature, with 116 deaths observed; 50 in the ribociclib arm and 66 in the placebo arm (hazard ratio 0.746; 95% CI 0.517-1.078). The ORR was 42.5% versus 28.7% for all patients treated with ribociclib plus letrozole versus placebo plus letrozole, respectively, and 54.5% versus 38.8%, respectively, for patients with measurable disease. Safety results, after a further 11.1 months of follow-up, were comparable with those reported at the first analysis, with no new or unexpected toxicities observed, and no evidence of cumulative toxicity. Conclusions: The improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole are maintained with longer follow-up, relative to letrozole monotherapy. Clinical trials number: NCT01958021.
650    _2
$a senioři $7 D000368
650    _2
$a aminopyridiny $x aplikace a dávkování $7 D000631
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a letrozol $x aplikace a dávkování $7 D000077289
650    _2
$a nádory jater $x farmakoterapie $x metabolismus $x sekundární $7 D008113
650    _2
$a nádory plic $x farmakoterapie $x metabolismus $x sekundární $7 D008175
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x metabolismus $x patologie $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a puriny $x aplikace a dávkování $7 D011687
650    _2
$a receptor erbB-2 $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a receptory progesteronu $x metabolismus $7 D011980
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stemmer, S M $u Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Burris, H A $u Sarah Cannon Research Institute, Nashville, USA.
700    1_
$a Yap, Y S $u Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
700    1_
$a Sonke, G S $u Medical Oncology, Netherlands Cancer Institute and BOOG Study Center, Amsterdam, the Netherlands.
700    1_
$a Paluch-Shimon, S $u Division of Oncology, Sheba Medical Center, Ramat Gan, Israel.
700    1_
$a Campone, M $u Department of Medical Oncology, Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain, France.
700    1_
$a Petrakova, K $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Blackwell, K L $u Department of Medicine, Duke University Medical Center, Durham.
700    1_
$a Winer, E P $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
700    1_
$a Janni, W $u Department of Gynecology, University of Ulm, Ulm, Germany.
700    1_
$a Verma, S $u Department of Oncology, Tom Baker Cancer Centre, Calgary, Canada.
700    1_
$a Conte, P $u Department of Surgery, Oncology and Gastroenterology and Division of Medical Oncology; University of Padua and Istituto Oncologico Veneto, IRCCS, Padua, Italy.
700    1_
$a Arteaga, C L $u Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA.
700    1_
$a Cameron, D A $u Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
700    1_
$a Mondal, S $u Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
700    1_
$a Su, F $u Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
700    1_
$a Miller, M $u Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
700    1_
$a Elmeliegy, M $u Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
700    1_
$a Germa, C $u Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
700    1_
$a O'Shaughnessy, J $u Texas Oncology-Baylor Charles A. Sammons Cancer Center and The US Oncology Research Network, Dallas, USA.
773    0_
$w MED00000432 $t Annals of oncology : official journal of the European Society for Medical Oncology $x 1569-8041 $g Roč. 29, č. 7 (2018), s. 1541-1547
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29718092 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082615 $b ABA008
999    __
$a ok $b bmc $g 1483739 $s 1084143
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 29 $c 7 $d 1541-1547 $e 20180701 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20200109
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace